OraSure Technologies, Inc. (OSUR): Price and Financial Metrics


OraSure Technologies, Inc. (OSUR): $9.84

0.05 (+0.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

OSUR Stock Summary

  • The price/operating cash flow metric for Orasure Technologies Inc is higher than 95.82% of stocks in our set with a positive cash flow.
  • For OSUR, its debt to operating expenses ratio is greater than that reported by only 8.71% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.12 for Orasure Technologies Inc; that's greater than it is for merely 9.55% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Orasure Technologies Inc are SCWX, BCOV, AVGR, GNSS, and VNDA.
  • OSUR's SEC filings can be seen here. And to visit Orasure Technologies Inc's official web site, go to www.orasure.com.

OSUR Stock Price Chart Interactive Chart >

Price chart for OSUR

OSUR Price/Volume Stats

Current price $9.84 52-week high $19.75
Prev. close $9.79 52-week low $9.26
Day low $9.60 Volume 923,900
Day high $9.98 Avg. volume 1,097,134
50-day MA $11.03 Dividend yield N/A
200-day MA $12.83 Market Cap 707.95M

OraSure Technologies, Inc. (OSUR) Company Bio


OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company was founded in 1979 and is based in Bethlehem, Pennsylvania.


OSUR Latest News Stream


Event/Time News Detail
Loading, please wait...

OSUR Latest Social Stream


Loading social stream, please wait...

View Full OSUR Social Stream

Latest OSUR News From Around the Web

Below are the latest news stories about Orasure Technologies Inc that investors may wish to consider to help them evaluate OSUR as an investment opportunity.

OraSure Technologies Submits COVID-19 Rapid Antigen Prescription Home Self-Test and Professional Test to FDA for Emergency Use Authorization

Tests designed to detect active COVID-19 infection with a simple, easy-to-use workflowBETHLEHEM, Pa., March 30, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it has submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its COVID-19 rapid antigen test for both Prescription Home Use, and Professional Use in point of care (POC) settings. These lateral flow, rapid diagnostic tests are designed to detect active COVID-19 infection with a simple, easy-to-use workflow, using samples self-collected from the lower nostrils. After users swab their lower nostrils, the test stick is swirled in a pre-measured buffer solution. No instrumentation, batteries, smart phone or laboratory analysis is needed ...

Yahoo | March 30, 2021

Raymond James: These 3 Stocks Are Poised to Surge by at Least 50%

In a recent note on the state of the stock markets, Raymond James equity strategist Tavis McCourt points out a series of policy factors that are playing a role in the current market volatility; the situation is more complex, perhaps, than most of us have been willing to admit. McCourt notes permutations of the SLR rule, political dynamics on the Senate Banking Committee, and the regulatory atmosphere towards potential capital return are all influencing the Fed’s moves and the market reactions.

Michael Marcus on TipRanks | March 10, 2021

Orasure Technologies Inc (OSUR) Q4 2020 Earnings Call Transcript

OSUR earnings call for the period ending December 31, 2020.

Yahoo | March 2, 2021

OraSure Technologies (OSUR) Q4 Earnings Miss Estimates

OraSure (OSUR) delivered earnings and revenue surprises of -57.14% and 7.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 1, 2021

Recap: OraSure Technologies Q4 Earnings

Shares of OraSure Technologies (NASDAQ:OSUR) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 50.00% over the past year to $0.03, which missed the estimate of $0.07. Revenue of $62,855,000 higher by 26.55% year over year, which beat the estimate of $57,290,000. Looking Ahead OraSure Sees Q1 Net Sales $55M-$60M Conference Call Details Date: Mar 01, 2021 Time: 05:00 PM View more earnings on OSUR ET Webcast URL: https://edge.media-server.com/mmc/p/95z6s52d Technicals Company's 52-week high was at $19.75 Company's 52-week low was at $5.23 Price action over last quarter: down 13.77% Company Description OraSure Technologies Inc is engaged in the development, manufacturing, and distribution of oral fluid diagnostic and collectio...

Yahoo | March 1, 2021

Read More 'OSUR' Stories Here

OSUR Price Returns

1-mo -6.99%
3-mo -29.06%
6-mo -34.00%
1-year -36.31%
3-year -42.29%
5-year 34.98%
YTD -7.04%
2020 31.82%
2019 -31.25%
2018 -38.07%
2017 114.81%
2016 36.34%

Continue Researching OSUR

Here are a few links from around the web to help you further your research on Orasure Technologies Inc's stock as an investment opportunity:

Orasure Technologies Inc (OSUR) Stock Price | Nasdaq
Orasure Technologies Inc (OSUR) Stock Quote, History and News - Yahoo Finance
Orasure Technologies Inc (OSUR) Stock Price and Basic Information | MarketWatch

Page generated in 1.0431 seconds.